Celadrin (Cetylated Fatty Acids)

Celadrin is a patented mixture of cetylated fatty acids, primarily cetyl myristoleate, that modulates inflammatory signaling by inhibiting arachidonic acid incorporation into cell membranes and suppressing pro-inflammatory cytokine production. It is used primarily for joint health, with both topical and oral formulations studied for reducing pain and improving mobility in osteoarthritis.

Origin & History

Celadrin is a patented blend of cetylated, esterified fatty acids (CFACs) including cetyl myristoleate, cetyl myristate, cetyl palmitoleate, cetyl laureate, cetyl palmitate, and cetyl oleate. It is derived from plant-based oils such as palm, palm kernel, olive, nutmeg, coconut, and unsaturated vegetable oils, then esterified (cetylated) and formulated with excipients like malto-dextrin and Arabic gum.

Historical & Cultural Context

No historical or traditional medicine use is documented in the available research. Celadrin is a modern, patented formulation without referenced traditional origins.

Health Benefits

• May reduce inflammatory markers (IL-6, MCP-1, TNF) based on in vitro macrophage studies (preliminary evidence)
• Promotes chondrogenic differentiation and cartilage matrix production in stem cell studies (preliminary evidence)
• May protect cartilage by preventing arachidonic acid incorporation (mechanism proposed, preliminary evidence)
• Potentially supports joint health in dogs per one unspecified canine study (very limited evidence)
• Could enhance production of cartilage components like aggrecan and collagen type II (in vitro evidence only)

How It Works

Celadrin's cetylated fatty acids incorporate into cell membranes and competitively inhibit the uptake of arachidonic acid, thereby reducing substrate availability for cyclooxygenase (COX) and lipoxygenase (LOX) enzymes that produce prostaglandins and leukotrienes. In vitro macrophage studies demonstrate downregulation of pro-inflammatory cytokines IL-6, MCP-1, and TNF-α, suggesting modulation of NF-κB signaling pathways. Additionally, stem cell research indicates Celadrin promotes chondrogenic differentiation via upregulation of cartilage matrix proteins including collagen type II and aggrecan.

Scientific Research

Evidence is limited to in vitro studies and animal research with no human clinical trials reported. One in vitro study (PMID: 29808705) tested Celadrin on RAW264.7 mouse macrophages and human adipose-derived stem cells, showing reduced inflammatory cytokines and enhanced chondrogenic markers, though no sample sizes were specified.

Clinical Summary

A randomized, double-blind trial (n=64) in osteoarthritis patients found that oral Celadrin (1,515 mg/day) significantly improved knee flexion and functional performance versus placebo after 68 days. Topical Celadrin cream demonstrated statistically significant reductions in pain and stiffness scores in a double-blind crossover study of 40 individuals with knee osteoarthritis within 30 minutes of application and after 30 days of use. In vitro macrophage and stem cell studies provide mechanistic support but represent preliminary evidence that cannot directly confirm clinical efficacy. Overall, evidence is promising but limited by small sample sizes and a lack of large-scale phase III trials.

Nutritional Profile

Celadrin (Cetylated Fatty Acids) is a patented blend of esterified fatty acid carbons (EFACs), not a traditional nutritional ingredient with macronutrients or micronutrients. Primary bioactive components are cetylated (esterified with cetyl alcohol/hexadecanol) fatty acids. Identified fatty acid constituents include: cetyl myristoleate (C14:1, the primary active component), cetyl myristate (C14:0), cetyl palmitoleate (C16:1), cetyl palmitate (C16:0), cetyl oleate (C18:1), cetyl laurate (C12:0), and cetyl stearate (C18:0). Cetyl myristoleate is the dominant compound, typically comprising the largest fraction of the blend. The esterification process links these fatty acids to cetyl alcohol, altering their biochemical behavior compared to free fatty acids. Contains no protein, carbohydrates, dietary fiber, vitamins, or minerals. Caloric contribution is that of a lipid (approximately 9 kcal/g theoretically), but it is used in supplemental doses (typically 350–1000 mg/day in human studies), not as a caloric food source. Bioavailability: The cetylated esterification is proposed to enhance membrane incorporation and lipid bilayer fluidity compared to non-esterified fatty acids, though pharmacokinetic data in vivo remains limited. Available in both oral and topical formulations; topical absorption has been demonstrated in human skin penetration studies.

Preparation & Dosage

No human clinical dosage ranges have been established. In vitro studies used concentrations of 0.7-1 mg/mL, with 0.7 mg/mL showing effects without toxicity in stem cells. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Glucosamine, Chondroitin, MSM, Boswellia, Hyaluronic Acid

Safety & Interactions

Celadrin is generally well tolerated in clinical trials, with no serious adverse events reported at oral doses of approximately 1,500 mg/day or with topical application. Because cetylated fatty acids may influence arachidonic acid metabolism similarly to NSAIDs, theoretical additive effects with anticoagulants such as warfarin or antiplatelet drugs like aspirin are possible, though not formally documented. Celadrin has not been adequately studied in pregnant or breastfeeding women, and use is not recommended in these populations due to insufficient safety data. Individuals with fish or shellfish allergies should verify the source of fatty acids in their specific product formulation before use.